The variant in TNFRSF1A is involved in Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), and can therefore be used as a novel pathogenic therapeutic target [65]. Here, TNFRSF1A is linked to TNF receptor 1-associated periodic fever syndrome.